BET BRD4 inhibitor compound II-25

CAS : 1660117-38-3

Ref. 3D-KRC11738

Informations sur le produit

• Nom: BET BRD4 inhibitor compound II-25

Description

BET BRD4 inhibitor compound II-25 belongs to a class of protein inhibitors. It is orally available and can inhibit cancer cells in vitro. BET BRD4 inhibitor compound II-25 has been shown to induce cell maturation and apoptosis in myeloid leukemia cells. This drug also inhibits the methyltransferase activity of the enzyme, thereby preventing the production of inflammatory cytokines that cause inflammation. In addition, this drug has shown potential as an anticancer therapeutic by inhibiting cancer cell proliferation and inducing tumor necrosis in vivo. It is possible that BET BRD4 inhibitor compound II-25 may function as a toll-like receptor modulator because it can block TLR signaling pathways in mice.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 429.51 g/mol
• Formule: C₂₅H₂₇N₅O₂
• Degré de pureté: Min. 95%